Worth reading
18Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Publication date25 August 2021
This document does not state the plan name, plan period, or numerical targets.
Key initiatives
01Further expand OEM development of disease-specific PHRs for pharmaceutical companies, covering 30+ disease areas
02Promote the adoption of disease-specific PHRs in clinical settings by healthcare institutions and patients, and expand the business
03Strengthen ePRO and data solutions for clinical research
04Further promote the adoption of Welby My Carte in primary care areas, including cardiovascular disease and diabetes
05Strengthen support through PHRs for individuals, organizations and healthcare institutions in response to COVID-19: vaccination management
06Strengthen personalized services for users: expand the pharmaceutical, medical device and food domains
07Promote a Real-World Data database linking data through individual IDs: health checkups, tests, prescriptions and PRO data
08Strengthen EMR/EHR integration centered on electronic medical records: data integration and deployment in clinical settings
09In addition to sponsored PHR development and use, expand SaaS/PaaS businesses using PHR services and data, as well as DTC (Direct to Customer) businesses, to strengthen the revenue base
Size of the Target MarketMarket B2B / Scale ¥640 billion / Source Dentsu, “Advertising Expenditures in Japan”, Market B2M / Scale ¥490.0 billion / Source Fuji Keizai, “Survey of the Domestic Market for Medical Information Systems”, Market B2C（B2B2C） / Scale ¥660 billion / Source Ministry of Economy, Trade and Industry, “International Economic Survey Project for Establishing an Integrated Domestic and External Economic Growth Strategy, FY2019”
Risks identified by the company
Potential erosion of competitive advantage due to new competitors entering the PHR industry
Concentration of revenue and profit in the fourth quarter, when foreign-affiliated pharmaceutical companies’ financial results are concentrated
Potential infringement of patients’ privacy due to the leakage of personal information and other incidents
Delays in decision-making by pharmaceutical companies and others, and longer order lead times, due to the spread of COVID-19
Revision, abolition or introduction of related laws and regulations and industry association rules
| Item | Details |
|---|---|
| Key initiatives | Further expand OEM development of disease-specific PHRs for pharmaceutical companies, covering 30+ disease areas, Promote the adoption of disease-specific PHRs in clinical settings by healthcare institutions and patients, and expand the business, Strengthen ePRO and data solutions for clinical research, Further promote the adoption of Welby My Carte in primary care areas, including cardiovascular disease and diabetes, Strengthen support through PHRs for individuals, organizations and healthcare institutions in response to COVID-19: vaccination management, Strengthen personalized services for users: expand the pharmaceutical, medical device and food domains, Promote a Real-World Data database linking data through individual IDs: health checkups, tests, prescriptions and PRO data, Strengthen EMR/EHR integration centered on electronic medical records: data integration and deployment in clinical settings, In addition to sponsored PHR development and use, expand SaaS/PaaS businesses using PHR services and data, as well as DTC (Direct to Customer) businesses, to strengthen the revenue base |
| Size of the Target Market | Market B2B / Scale ¥640 billion / Source Dentsu, “Advertising Expenditures in Japan”, Market B2M / Scale ¥490.0 billion / Source Fuji Keizai, “Survey of the Domestic Market for Medical Information Systems”, Market B2C（B2B2C） / Scale ¥660 billion / Source Ministry of Economy, Trade and Industry, “International Economic Survey Project for Establishing an Integrated Domestic and External Economic Growth Strategy, FY2019” |
| Risks identified | Potential erosion of competitive advantage due to new competitors entering the PHR industry, Concentration of revenue and profit in the fourth quarter, when foreign-affiliated pharmaceutical companies’ financial results are concentrated, Potential infringement of patients’ privacy due to the leakage of personal information and other incidents, Delays in decision-making by pharmaceutical companies and others, and longer order lead times, due to the spread of COVID-19, Revision, abolition or introduction of related laws and regulations and industry association rules |
| Publication date | 25 August 2021 |
Items this document does not state (21)
Plan namePlan periodProgress against the planSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased despite some order delays and other impacts from COVID-19. Operating profit declined due mainly to increased investment in development personnel to support business expansion.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.